US equities |
SPCX $166.37 ▲+4.66% NVDA $236.69 ▲+1.17% MU $1,063.30 ▼-1.08% TSLA $377.65 ▲+1.91% MSFT $526.00 ▲+1.64% SNDK $1,708.81 ▼-0.65% INTC $117.04 ▼-1.92% META $745.15 ▲+2.34%
FinancialContent

InflaRx N.V. - Common Stock (NQ:IFRX)

1.675 -0.045 (-2.62%)
Delayed Quote Updated: 11:43 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about InflaRx N.V. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx to Host Virtual Capital Markets Day
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Announces Participation in September Investor Conferences
From InflaRx N.V.
Via GlobeNewswire
InflaRx (NASDAQ:IFRX) Tumbles After Q2 Results Miss Estimates ↗
Via Chartmill
IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases ↗
Via Stocktwits
News headline image
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline ↗
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company... 
Via MarketBeat
News headline image
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
From InflaRx N.V.
Via GlobeNewswire
News headline image
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
From InflaRx N.V.
Via GlobeNewswire
Friday's session: top gainers and losers ↗
Via Chartmill
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Is InflaRx NV Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
These stocks have an unusual volume in today's session ↗
Volume analysis on 2025-11-12: stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
Earnings Season: Synergy CHC (NASDAQ: SNYR) FOCUSfactor® Beverage – Eyes $100M+ in 2026 – More Stocks Reporting Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-10: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
These stocks are the most active in today's session ↗
Monday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity! 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst ↗
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases. 
Via Benzinga
News headline image
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge ↗
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >